|
Jul 9
|
Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements
|
|
Jun 25
|
Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development
|
|
Jun 24
|
Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement
|
|
Jun 11
|
Ernexa Therapeutics announces 1-for-15 reverse stock split
|
|
May 28
|
Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025
|
|
Dec 21
|
Eterna Therapeutics Appoints Sanjeev Luther as President and CEO
|
|
Dec 20
|
Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer
|
|
Jul 18
|
Eterna Therapeutics Announces $8.7M Private Placement Transaction
|
|
Jul 18
|
Eterna Therapeutics Announces Completion of $8.7 Million of Convertible Debt Financing
|